Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia [0.03%]
博苏替尼：一种SRC-ABL酪氨酸激酶抑制剂用于慢性粒细胞白血病的治疗
Fuad El Rassi,Hanna Jean Khoury
Fuad El Rassi
Bosutinib is one of five tyrosine kinase inhibitors commercially available in the United States for the treatment of chronic myeloid leukemia. This review of bosutinib summarizes the mode of action, pharmacokinetics, efficacy and safety dat...
Rima Chakraborty,Carilyn N Wieland,Nneka I Comfere
Rima Chakraborty
The advent of personalized medicine has ushered in a new era for cancer therapy with a significant impact on the management of advanced melanoma. Molecular targeted therapies have shown promise in the management of various malignancies, inc...
Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen [0.03%]
泰国绝经后乳腺癌患者接受他莫昔芬辅助治疗与无病生存率之间的关系及其CYP2D6和CYP2C19多态性的关联研究
Montri Chamnanphon,Khunthong Pechatanan,Ekapob Sirachainan et al.
Montri Chamnanphon et al.
Purpose: To investigate the impact of CYP2D6 and CYP2C19 polymorphisms in predicting tamoxifen efficacy and clinical outcomes in Thai breast cancer patients. ...
Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategies [0.03%]
非小细胞肺癌的分子靶向治疗和个性化医疗-药物耐受性、机制及策略
Marybeth Sechler,Amber D Cizmic,Sreedevi Avasarala et al.
Marybeth Sechler et al.
Targeted therapies for cancer bring the hope of specific treatment, providing high efficacy and in some cases lower toxicity than conventional treatment. Although targeted therapeutics have helped immensely in the treatment of several cance...
Copy number variation in sulfotransferase isoform 1A1 (SULT1A1) is significantly associated with enzymatic activity in Japanese subjects [0.03%]
日本人大样本中SULT1A1基因拷贝数变异与南方 bud酶活性显著相关性研究
Xinfeng Yu,Takahiro Kubota,Ishwori Dhakal et al.
Xinfeng Yu et al.
Sulfotransferase isoform 1A1 (SULT1A1) plays a key role in the metabolism of a variety of endo- and xenobiotics and it's activity could influence response to drugs. Our previous studies have focused on the impact of genetic variants of SULT...
GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer [0.03%]
头颈癌患者复发和/或第二原发肿瘤的风险预测因素：基因多态性的影响
Xuemei Zhang,Maosheng Huang,Xifeng Wu et al.
Xuemei Zhang et al.
The objective of this study was to determine copy number variant (CNV) and promoter genetic variants in glutathione S-transferase Mu class 1 (GSTM1) and the risk of recurrence (REC)/second primary tumor (SPT) in patients with previously dia...
Importance of pharmacogenetics in the treatment of children with attention deficit hyperactive disorder: a case report [0.03%]
儿童注意缺陷多动障碍治疗中的药物基因组学重要性：一例报告
Teerarat Tan-Kam,Chutamanee Suthisisang,Chosita Pavasuthipaisit et al.
Teerarat Tan-Kam et al.
This case report highlights the importance of pharmacogenetic testing in the treatment of attention deficit hyperactive disorder (ADHD). A 6-year-old boy diagnosed with ADHD was prescribed methylphenidate 5 mg twice daily (7 am and noon) an...
CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients [0.03%]
泰国乳腺癌患者中CYP2D6基因多态性影响辅助他莫昔芬疗效
Ekaphop Sirachainan,Sureerat Jaruhathai,Narumol Trachu et al.
Ekaphop Sirachainan et al.
Aim: We evaluated single nucleotide polymorphisms (SNPs) of CYP2D6 to identify those that influence the efficiency of tamoxifen in adjuvant treatment of breast cancer through a matched case-control study. ...
Drug targets and predictive biomarkers in the management of metastatic melanoma [0.03%]
药物靶点和预测生物标志物在转移性黑色素瘤管理中的作用
Jaykumar Thumar,Eva Giesen,Harriet M Kluger
Jaykumar Thumar
Melanoma is the leading cause of fatal skin cancer, and in the past few decades, there has been an increase in the incidence of and mortality from metastatic melanoma. Until recently, the therapeutic options for treatment of metastatic mela...
François Habersetzer,Céline Leboeuf,Michel Doffoël et al.
François Habersetzer et al.
Boceprevir was the first agent, along with telaprevir, of a novel class of direct-acting antivirals that entered clinical practice for the treatment of chronic hepatitis C. Boceprevir is an antiprotease that directly blocks hepatitis C viru...